HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $27 price target on the stock.
December 05, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma with a $27 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $27 price target by a reputable analyst could lead to increased investor confidence in MRNS, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100